相似文献
1
AKR1C3 Promotes AR-V7 Protein Stabilization and Confers Resistance to AR-Targeted Therapies in Advanced Prostate Cancer.
Mol Cancer Ther. 2019 Oct;18(10):1875-1886. doi: 10.1158/1535-7163.MCT-18-1322. Epub 2019 Jul 15.
2
Cross-Resistance Among Next-Generation Antiandrogen Drugs Through the AKR1C3/AR-V7 Axis in Advanced Prostate Cancer.
Mol Cancer Ther. 2020 Aug;19(8):1708-1718. doi: 10.1158/1535-7163.MCT-20-0015. Epub 2020 May 19.
3
Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer.
Cancer Res. 2015 Apr 1;75(7):1413-22. doi: 10.1158/0008-5472.CAN-14-3080. Epub 2015 Feb 3.
4
Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer.
Mol Oncol. 2020 Oct;14(10):2455-2470. doi: 10.1002/1878-0261.12770. Epub 2020 Aug 9.
5
Niclosamide enhances abiraterone treatment via inhibition of androgen receptor variants in castration resistant prostate cancer.
Oncotarget. 2016 May 31;7(22):32210-20. doi: 10.18632/oncotarget.8493.
6
Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Mol Cancer Ther. 2017 Jan;16(1):35-44. doi: 10.1158/1535-7163.MCT-16-0186. Epub 2016 Oct 28.
7
KIF15-Mediated Stabilization of AR and AR-V7 Contributes to Enzalutamide Resistance in Prostate Cancer.
Cancer Res. 2021 Feb 15;81(4):1026-1039. doi: 10.1158/0008-5472.CAN-20-1965. Epub 2020 Dec 4.
8
Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
Oncogene. 2023 Feb;42(9):693-707. doi: 10.1038/s41388-022-02566-6. Epub 2023 Jan 3.
9
TAS3681, an androgen receptor antagonist, prevents drug resistance driven by aberrant androgen receptor signaling in prostate cancer.
Mol Oncol. 2024 Aug;18(8):1980-2000. doi: 10.1002/1878-0261.13641. Epub 2024 Apr 10.
10
Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.
引用本文的文献
1
Androgen Receptor Signalling in Prostate Cancer: Mechanisms of Resistance to Endocrine Therapies.
Res Rep Urol. 2025 Jun 21;17:211-223. doi: 10.2147/RRU.S388265. eCollection 2025.
2
Aldo-keto reductase family 1 member C3 mediates radioresistance of esophageal cancer cells through suppressing MAPK and AKT signaling.
BMC Cancer. 2024 Oct 7;24(1):1236. doi: 10.1186/s12885-024-13012-z.
3
LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy.
Cancer Res. 2024 Nov 4;84(21):3617-3628. doi: 10.1158/0008-5472.CAN-24-0440.
4
Knockdown of AMIGO2 suppresses proliferation and migration through regulating PPAR-γ in bladder cancer.
Hereditas. 2024 Jul 8;161(1):21. doi: 10.1186/s41065-024-00325-z.
5
Molecular landscape for risk prediction and personalized therapeutics of castration-resistant prostate cancer: at a glance.
Front Endocrinol (Lausanne). 2024 Jun 3;15:1360430. doi: 10.3389/fendo.2024.1360430. eCollection 2024.
6
Discovery of an Aldo-Keto reductase 1C3 (AKR1C3) degrader.
Commun Chem. 2024 Apr 29;7(1):95. doi: 10.1038/s42004-024-01177-4.
7
AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies.
Front Pharmacol. 2024 Mar 8;15:1378292. doi: 10.3389/fphar.2024.1378292. eCollection 2024.
8
The Potential Preventive and Therapeutic Roles of NSAIDs in Prostate Cancer.
Cancers (Basel). 2023 Nov 16;15(22):5435. doi: 10.3390/cancers15225435.
9
Aldo-Keto Reductase 1C3 Inhibitor Prodrug Improves Pharmacokinetic Profile and Demonstrates In Vivo Efficacy in a Prostate Cancer Xenograft Model.
J Med Chem. 2023 Jul 27;66(14):9894-9915. doi: 10.1021/acs.jmedchem.3c00732. Epub 2023 Jul 10.
10
Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment.
J Immunother Cancer. 2023 May;11(5). doi: 10.1136/jitc-2022-006581.
本文引用的文献
1
A positive role of c-Myc in regulating androgen receptor and its splice variants in prostate cancer.
Oncogene. 2019 Jun;38(25):4977-4989. doi: 10.1038/s41388-019-0768-8. Epub 2019 Feb 28.
2
Proteostasis by STUB1/HSP70 complex controls sensitivity to androgen receptor targeted therapy in advanced prostate cancer.
Nat Commun. 2018 Nov 16;9(1):4700. doi: 10.1038/s41467-018-07178-x.
3
Diverse AR-V7 cistromes in castration-resistant prostate cancer are governed by HoxB13.
Proc Natl Acad Sci U S A. 2018 Jun 26;115(26):6810-6815. doi: 10.1073/pnas.1718811115. Epub 2018 May 29.
4
Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.
Proc Natl Acad Sci U S A. 2018 May 15;115(20):E4584-E4593. doi: 10.1073/pnas.1802415115. Epub 2018 Apr 30.
5
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.
N Engl J Med. 2018 Apr 12;378(15):1408-1418. doi: 10.1056/NEJMoa1715546. Epub 2018 Feb 8.
6
Niclosamide and Bicalutamide Combination Treatment Overcomes Enzalutamide- and Bicalutamide-Resistant Prostate Cancer.
Mol Cancer Ther. 2017 Aug;16(8):1521-1530. doi: 10.1158/1535-7163.MCT-16-0912. Epub 2017 May 12.
7
Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
Clin Cancer Res. 2017 Aug 15;23(16):4704-4715. doi: 10.1158/1078-0432.CCR-17-0017. Epub 2017 May 4.
8
c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.
EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.
9
Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer.
Mol Cancer Ther. 2017 Jan;16(1):35-44. doi: 10.1158/1535-7163.MCT-16-0186. Epub 2016 Oct 28.
10
AR-v7 protein expression is regulated by protein kinase and phosphatase.
Oncotarget. 2015 Oct 20;6(32):33743-54. doi: 10.18632/oncotarget.5608.
Zotero 插件